Journals / Viral Hepatitis Journal / 2016 / Cilt: 22 - Sayı: 1

Antiviral Treatment During Breastfeeding in Hepatitis B

Hepatit B'de Emzirme Döneminde Antiviral Tedavi

Pages
1–5
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, further studies are urgently needed in this issue to make a recommendation supported by evidence-based medicine.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:From 1982, with the availability of hepatitis B vaccine, chronic hepatitis B infection rate and its complications have decreased dramatically.
📊
Key Findings & Data:Mothers with high concentrations of HBV DNA (>1.000.000 copies/ml) should be considered for antiviral therapy.
💡
Conclusion & Impact:However, further studies are urgently needed in this issue to make a recommendation supported by evidence-based medicine.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

From 1982, with the availability of hepatitis B vaccine, chronic hepatitis B infection rate and its complications have decreased dramatically. Today, transmission from an infected woman to her newborn still remains as one of the major problems about hepatitis B. Guidelines recommend quantification of hepatitis B virus (HBV) DNA in all infected pregnant women at the end of the second trimester. Mothers with high concentrations of HBV DNA (>1.000.000 copies/ml) should be considered for antiviral therapy. Since the immune system is activated after delivery, continuing this therapy during the postpartum period remains critical in highly viremic mothers. Some antiviral drugs are recommended during pregnancy. However, safety of these drugs during breastfeeding interestingly remains unclear. There are several studies regarding the use of lamivudine (LAM) and tenofovir disoproxil (TdF) while breastfeeding in human immunodeficiency virus (HIV)-infected mothers. The World Health Organization guidelines on HIV recommend HIV-infected mothers to continue antiretroviral treatment while breastfeeding. Applicability of this recommendation for HBV-infected mothers must be clarified.Both clinicians and patients face therapeutic decisions regarding breastfeeding in hepatitis B, which are not based on randomized controlled trials. They have to make a hard decision to choose the best option considering both the benefits of breastfeeding and the need for antiviral treatment, where indicated, to have a healthy mother, which seem to contradict to some extent. In the light of up-to-date literature, if a mother needs antiviral treatment for HBV, LAM and TdF raise as options with advantages of enabling breastfeeding. However, further studies are urgently needed in this issue to make a recommendation supported by evidence-based medicine.

Özet

1982 yılında hepatit B aşısının kullanılmaya başlanması ile kronik hepatit B enfeksiyonu ve komplikasyonlarında dramatik bir düşüş gözlenmiştir. Günümüzde hala enfekte anneden bebeğe bulaş, hepatit B ile ilgili en büyük problemlerden birini oluşturmaktadır. Hepatit B virüsü (HBV) ile enfekte gebelerde ikinci trimestırda HBV DNA kantitasyonu yapılması önerilmektedir. HBV DNA düzeyi 1,000,000 kopya/ml üzerinde olan gebelerin antiviral tedavi açısından değerlendirilmesi gerekmektedir. Postpartum dönemde gelişen immün sistem reaktivasyonu nedeniyle, antiviral tedavinin doğum sonrası dönemde de devam etmesi virüs titresi yüksek annelerde kritik öneme sahiptir. Bazı antiviral ilaçlar gebelik döneminde önerilseler de emzirme döneminde kullanımlarının güvenilirliği ile ilgili net bir veri bulunmamaktadır. Lamivudin (LAM) ve tenofovirin (TdF), insan bağışıklık yetmezlik virüsü (HIV) ile enfekte annelerde emzirme döneminde kullanımları ile ilgili çalışmaları vardır. Dünya Sağlık Örgütü HIV rehberinde HIV ile enfekte annelerin antiretroviral tedavi alırken emzirmeye devam edebilecekleri önerilmektedir. Bu önerinin HBV ile enfekte anneler için de net ortaya konması gerekmektedir. Gerek klinisyenler gerekse hastalar günlük pratikte hepatit B ile enfekte annenin emzirme kararını, randomize kontrollü çalışmalara dayanmayan verilerle almak durumuyla karşı karşıya kalmaktadır. Hem emzirmenin faydalarını hem de hastaların antiviral tedavi gereksinimini göz önünde bulundururarak zor bir karar vermeleri gerekmektedir. Güncel bilgiler ışığında, bir annenin antiviral tedavi ihtiyacı varsa emzirmeye olanak sağlamaları nedeniyle LAM ve TdF iyi birer alternatif olarak karşımıza çıkmaktadır. Fakat yine de kanıta dayalı tıp ile desteklenmiş önerilerde bulunabilmek için daha fazla çalışmaya ihtiyaç vardır.

🔖

Cite This Article

HASANOĞLU, İ., GÜNER, R. (2016). Antiviral Treatment During Breastfeeding in Hepatitis B. Viral Hepatitis Journal, Cilt: 22 - Sayı: 1, 1–5. https://ajindex.com/articles/332813

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. WHO | Hepatitis B [Internet]. WHO. [cited 2015 Nov 30]. Available from: http://www.who.int/mediacentre/factsheets/ fs204_Jul2014/en/ 2. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012
  2. Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, Gulsun S, Barcin T, Kalkanli S, Dal MS, Ayaz C. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol. 2013
  3. Tekin Koruk S, Batirel A, Kose S, Cetin Akhan S, Aygen B, Tulek N, Hatipoglu C, Bulut C, Yıldız O, Sacligil C, Sirmatel F, Altunok E. Evaluation of hepatitis B virus transmission and antiviral therapy among hepatitis B surface antigen-positive pregnant women. J Obstet Gynaecol Res. 2015
  4. Ertürk A, Cüre E, Parlak E, Cüre MC, Çapur Çİçek A, Kır Şahin F. Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B. Viral Hepatits J. 2014
  5. Ahn J, Salem SB, Cohen SM. Evaluation and management of hepatitis B in pregnancy: a survey of current practices. Gastroenterol Hepatol (N Y). 2010
  6. Giles ML, Garland SM, Grover SR, Lewin SM, Hellard ME. Impact of an education campaign on management in pregnancy of women infected with a blood-borne virus. Med J Aust. 2006
  7. de Oliveira PR, Yamamoto AY, de Souza CB, de Araújo NM, de Andrade Gomes S, Heck AR, de Castro Figueiredo JF, Mussi-Pinhata MM. Hepatitis B viral markers in banked human milk before and after Holder pasteurization. J Clin Virol. 2009
  8. Chen X, Chen J, Wen J, Xu C, Zhang S, Zhou YH, Hu Y. Breastfeeding is not a risk factor for mother-to-child transmission of hepatitis B virus. PloS One. 2013
  9. 55303. 10. Shi Z, Yang Y, Wang H, Ma L, Schreiber A, Li X, Sun W, Zhao X, Yang X, Zhang L, Lu W, Teng J, An Y. Breastfeeding of newborns by mothers carrying hepatitis B virus: a metaanalysis and systematic review. Arch Pediatr Adolesc Med. 2011
  10. Zheng Y, Lu Y, Ye Q, Xia Y, Zhou Y, Yao Q, Wei S. Should chronic hepatitis B mothers breastfeed? a meta analysis. BMC Public Health. 2011
  11. Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A. The next generation of the World Health Organization's global antiretroviral guidance. J Int AIDS Soc. 2013
  12. 18757. 13. Xu W-M, Cui Y-T, Wang L, Yang H, Liang Z-Q, Li X-M, Zhang SL, QİAO F